Hims & Hers in Talks with Novo Nordisk for Wegovy and New Obesity Pill, Expands into Lab Testing and Longevity

Hims & Hers Health, Inc., a leading telehealth platform, has announced it is in active discussions with Novo Nordisk to offer Wegovy injections and a forthcoming oral obesity drug through its online platform. This potential partnership comes as Hims & Hers continues to expand its weight loss business and explores new avenues in personalized healthcare.

Renewed Partnership Talks and Weight Loss Vertical Growth

Hims & Hers revealed during its third-quarter earnings call that it is engaged in talks with Novo Nordisk to renew their partnership. The company's stock jumped 6% in post-market trading following this announcement. Andrew Dudum, co-founder and CEO of Hims & Hers, emphasized the importance of offering a broad range of treatment options to patients.

The potential agreement would allow Hims & Hers to distribute Wegovy injections and Novo Nordisk's oral obesity drug, which is expected to launch in the U.S. next year pending FDA approval. This development follows a brief collaboration between the two companies in June, which was terminated due to concerns over Hims & Hers selling compounded GLP-1 drugs.

Hims & Hers' weight loss business continues to be a major focus, with CFO Yemi Okupe projecting $725 million in revenue from this segment in 2025. The company has also expanded its offerings to include compounded semaglutide and recently introduced compounded GLP-1 microdosing treatment plans.

Expansion into Lab Testing and Longevity Services

In addition to its weight loss initiatives, Hims & Hers announced plans to launch comprehensive whole-body lab testing before the end of the year. This new service aims to provide customers with affordable access to insights for monitoring and improving their overall health.

The company also revealed its intention to enter the longevity market in 2026. This new specialty will feature a range of therapies, including peptides, coenzymes, GLP, and GIP treatments designed to enhance performance, recovery, and cardiometabolic longevity markers.

Financial Performance and Subscriber Growth

Hims & Hers reported strong financial results for the third quarter of 2025, with revenue increasing 49% year-over-year to $599 million, surpassing Wall Street estimates. The company's subscriber base grew to over 2.5 million, a 21% increase from the previous year.

Net income for the quarter was $15.8 million, or earnings per share of 6 cents, slightly below analyst expectations. The company narrowed its full-year revenue guidance to a range of $2.335 billion to $2.355 billion and adjusted EBITDA guidance to $307 million to $317 million.